Filing Details
- Accession Number:
- 0001209191-22-013994
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-03-01 16:19:26
- Reporting Period:
- 2022-02-25
- Accepted Time:
- 2022-03-01 16:19:26
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1346830 | Cara Therapeutics Inc. | CARA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1706426 | Scott Terrillion | C/O Cara Therapeutics, Inc. 4 Stamford Plaza, 107 Elm Street, 9Th Fl Stamford CT 06902 | Sec'y; Chief Compliance & G.c. | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-02-25 | 20,000 | $0.00 | 102,412 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2022-02-25 | 1,972 | $10.29 | 100,440 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2022-02-28 | 5,333 | $0.00 | 105,773 | No | 4 | A | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | A | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to Buy) | Acquisiton | 2022-02-25 | 40,000 | $0.00 | 40,000 | $10.46 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 40,000 | 2032-02-25 | No | 4 | A | Direct |
Footnotes
- Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of February 25, 2023, February 25, 2024 and February 25, 2025, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.
- This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs reported in the Form 4 filed with the Securities and Exchange Commission on August 26, 2021, and does not represent a discretionary trade by the Reporting Person.
- Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer'ssatisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were notreportable under Section 16 until vesting was determined, which occurred on February 28, 2022. The vested shares represents the last of threepossible vesting events of the total number of shares subject to the award. Each RSU represents the contingent right to receive one share of common stock of theIssuer.
- The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on March 25, 2022, in each case subject to the Reporting Person's continued service as of each such date.
Billionaire Hedge Funds
